Who are CorMedix Inc.'s main suppliers?

CorMedix Inc. (CRMD) key suppliers include: Ligand Pharmaceuticals Incorporated, ORANY, ORANY, Monolithic Power Systems, Inc.. View the full supplier network at chainsifter.com/chain/CRMD.

Who are CorMedix Inc.'s major customers?

CorMedix Inc. (CRMD) key customers include: DIALYSIS-ORGANIZATION, TOP-THREE-CUSTOMERS, Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, ORANY and 7 more. View the full customer network at chainsifter.com/chain/CRMD.

What sector is CorMedix Inc. in?

CorMedix Inc. (CRMD) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

CorMedix Inc. Suppliers, Customers & Supply Chain (CRMD)

4Suppliers

12Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

CorMedix Inc. (CRMD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

20Total relationships

5Distinct source URLs

6High confidence

0.741Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

CorMedix Inc. Suppliers

Ticker	Name	Confidence	Evidence
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from CRMD graph: Reciprocal relationship from LGND graph: Reciprocal relationship from CRMD graph: Reciprocal relationship from LGND g…
ORANY	ORANY	72%	e pharmaceutical ingredients (“APIs”) for DefenCath, taurolidine and heparin sodium, respectively. With regards to taurolidine, we have a drug master file (“DMF”) filed with the FDA. There is a maste…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from CRMD graph: e pharmaceutical ingredients (“APIs”) for DefenCath, taurolidine and heparin sodium, respectively. With regards to t…
MPWR	Monolithic Power Systems, Inc.	62%	Reciprocal relationship from MPWR graph: Reciprocal relationship from CRMD graph: Reciprocal relationship from MPWR graph: manufacturing footprint across multiple countries helps mitigate operational…

CorMedix Inc. Customers

Ticker	Name	Confidence	Evidence
DIALYSIS-ORGANIZATION	DIALYSIS-ORGANIZATION	92%	DefenCath sales increased year over year largely due to the onboarding of a large dialysis organization in mid-2025
TOP-THREE-CUSTOMERS	TOP-THREE-CUSTOMERS	92%	Sales to our top three customers accounted for 79% of our total revenue for the year ended December 31, 2025
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from CRMD graph: .S. market since 2015. Market Opportunity MINOCIN IV addresses a defined but persistent market opportunity within the…
LGND	Ligand Pharmaceuticals Incorporated	72%	.S. market since 2015. Market Opportunity MINOCIN IV addresses a defined but persistent market opportunity within the U.S. hospital anti-infectives market, particularly in the treatment of serious in…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from CRMD graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CRMD graph: ices. Further, the development of…
ORANY	ORANY	72%	ices. Further, the development of new treatment methods could render DefenCath non-competitive or obsolete. We believe that the key competitive factors that will affect the commercial success of Defe…
CYDEX-PHARMACEUTICALS-INC	CYDEX-PHARMACEUTICALS-INC	62%	.S. market since 2015. Market Opportunity MINOCIN IV addresses a defined but persistent market opportunity within the U.S. hospital anti-infectives market, particularly in the treatment of serious in…
MELINTA-THERAPEUTICS-LLC	MELINTA-THERAPEUTICS-LLC	62%	s of the chargeback rates, Medicaid pricing information and other regulatory factors. Our testing involved assessing the historical accuracy of management’s estimates by comparing actual activity to …
NAPP-PHARMACEUTICAL-GROUP-LIMITED	NAPP-PHARMACEUTICAL-GROUP-LIMITED	62%	es that could be highly synergistic with our existing or future sales infrastructure deployment. Promoted Commercial Products DefenCath On November 15, 2023, we announced that the FDA approved the ne…
OVERVIEW-CORMEDIX-INC	OVERVIEW-CORMEDIX-INC	62%	rward-looking statements, and such forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Investors should not place undue reliance on these statements. CorMedix …
PICTON-HOLDING-COMPANY-INC	PICTON-HOLDING-COMPANY-INC	62%	.S. market since 2015. Market Opportunity MINOCIN IV addresses a defined but persistent market opportunity within the U.S. hospital anti-infectives market, particularly in the treatment of serious in…
WAKUNAGA-PHARMACEUTICAL-COMPANY-LTD	WAKUNAGA-PHARMACEUTICAL-COMPANY-LTD	62%	.S. market since 2015. Market Opportunity MINOCIN IV addresses a defined but persistent market opportunity within the U.S. hospital anti-infectives market, particularly in the treatment of serious in…

CorMedix Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CRMD-DEBT-8859	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
CRMD-DEBT-8858	Warrants outstanding: 3310000	90%	xbrl warrant detail from xbrl 2025-12-31.
CRMD-DEBT	Debt stack $147.4M	90%	Market cache reports total debt of $147.4M.

CorMedix Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for CorMedix Inc..

CorMedix Inc. Ownership

Holder	Name	Confidence	Evidence
CRMD-OWNER-DEEP-TRACK-CAPITAL-LP	Deep Track Capital, LP	90%	13F overlay lists Deep Track Capital, LP as top holder; 192 tracked holders.

CorMedix Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
OBIO	Orchestra BioMed Holdings, Inc.	100.00	2
ELUT	Elutia Inc.	100.00	2
MPWR	Monolithic Power Systems, Inc.	100.00	1	['supplier']
VKTX	Viking Therapeutics, Inc.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
LGND	Ligand Pharmaceuticals Incorporated	100.00	1	['customer', 'supplier']
AGEN	Agenus Inc.	100.00	2
SGMO	Sangamo Therapeutics, Inc.	100.00	2
OVID	Ovid Therapeutics Inc.	100.00	2
PLX	Protalix BioTherapeutics, Inc.	100.00	2
LONA	LeonaBio, Inc.	100.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
BFRGW	BullFrog AI Holdings, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
ARQQW	Arqit Quantum Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
ASBPW	Aspire Biopharma Holdings, Inc.	50.00	2
BCDRF	Banco Santander, S.A.	50.00	2
BSX	Boston Scientific Corporation	50.00	2
EPDU	ENTERPRISE PRODUCTS PARTNERS L.P.	50.00	2

CorMedix Inc. Supply Chain